Schizophrenia affects roughly 1 in 345 people worldwide, or about 24 million people globally. Among adults specifically, the rate is higher: about 1 in 233, or 0.43%. In the United States, estimates range between 0.25% and 0.64% of the population depending on how studies define and measure the condition.
Lifetime Risk vs. Current Prevalence
There’s an important difference between how many people have schizophrenia right now and how many will develop it at some point during their lives. The lifetime risk is often quoted as 1 in 100, but more rigorous studies put the global average closer to 0.72%. That gap matters because schizophrenia is a lifelong condition, and some people develop it later than expected. Globally, about 15 new cases per 100,000 people are diagnosed each year.
Who Develops It and When
Schizophrenia can appear at any age, but it typically emerges in late adolescence or early adulthood. Men tend to develop it 3 to 4 years earlier than women, with a peak between ages 20 and 29. Women show a different pattern: a first peak between 20 and 39, followed by a second surge around menopause. This second wave is likely related to declining estrogen levels, which appear to have a protective effect earlier in life.
Before age 40, schizophrenia is more common in men. After 40, the balance shifts, and women make up a larger share of new diagnoses. This gender timing difference is one of the most consistent findings across countries and study methods.
Genetic Risk
Your risk rises substantially if a close family member has schizophrenia. In the general population, the lifetime risk sits just under 1%. For first-degree relatives (a parent, sibling, or child with the condition), that jumps to about 6.5%. For identical twins, the risk exceeds 40%. That last number is telling: if schizophrenia were purely genetic, identical twins would share the diagnosis nearly 100% of the time. The fact that more than half of identical twins of affected individuals never develop schizophrenia shows that environmental factors play a significant role alongside genetics.
Urban vs. Rural Differences
People born or raised in cities face a notably higher risk. A meta-analysis found that living in a highly urbanized area roughly doubles the risk of developing schizophrenia compared to living in a very rural environment. A large Danish study found that neighborhood-level factors, such as population density and local social conditions, explained most of this urban effect. After accounting for both individual characteristics and neighborhood features, the elevated risk from urban living dropped from about double to around 30% higher. In other words, it’s not just the density of a city that drives risk, but specific environmental and social conditions that tend to cluster in urban areas.
Life Expectancy and Physical Health
Schizophrenia carries severe consequences beyond its psychiatric symptoms. People with the condition die significantly earlier than the general population. Studies estimate a life expectancy reduction of roughly 15 to 17 years, with one large study finding a mean age at death of just 59.
About two-thirds of this excess mortality comes from natural causes, not suicide or accidents. Cardiovascular disease is the single biggest killer, accounting for nearly 28% of deaths. Infections account for another 17%. Heart attacks and coronary artery disease are leading causes of sudden death in this population, driven by a combination of medication side effects, physical inactivity, poor diet, and barriers to accessing routine healthcare. Violent deaths, including suicide and accidents, account for about 17% of mortality, with younger individuals facing particularly elevated risk from both suicide and physical health complications.
Substance Use
Substance use disorders overlap heavily with schizophrenia. Estimates of lifetime substance use disorders in people with schizophrenia range from 47% to 70%. When tobacco use is included, that figure climbs to 80% or higher. This isn’t just a side issue: substance use worsens symptoms, complicates treatment, and contributes to the physical health problems that shorten life expectancy.
Economic Cost
Despite being relatively uncommon compared to conditions like depression or anxiety, schizophrenia carries an outsized economic burden. A 2024 analysis in JAMA Psychiatry estimated $147.5 billion in caregiver-related costs alone in the United States, including unpaid labor from family members, out-of-pocket spending, and additional healthcare expenses. Total societal costs encompass direct medical care, lost productivity, supportive housing, long-term care, and costs associated with incarceration and homelessness, both of which disproportionately affect people with schizophrenia.